Primary and Secondary Infections by Human Parvovirus B19 following Bone Marrow Transplantation: Characterization by PCR and B-Cell Molecular Immunology

1997 ◽  
Vol 29 (2) ◽  
pp. 129-135 ◽  
Author(s):  
Maria Söderlund ◽  
Petri Ruutu ◽  
Tapani Ruutu ◽  
Kari Asikainen ◽  
Rauli Franssila ◽  
...  
1993 ◽  
Vol 44 (3) ◽  
pp. 207-209 ◽  
Author(s):  
A. Azzi ◽  
R. Fanci ◽  
S. Ciappi ◽  
K. Zakrzewska ◽  
A. Bosi

Infection ◽  
1999 ◽  
Vol 27 (2) ◽  
pp. 114-117 ◽  
Author(s):  
M. Schleuning ◽  
G. Jäger ◽  
E. Holler ◽  
W. Hill ◽  
C. Thomssen ◽  
...  

1998 ◽  
Vol 100 (4) ◽  
pp. 195-199 ◽  
Author(s):  
Shoichi Kobayashi ◽  
Atsuo Maruta ◽  
Toshiharu Yamamoto ◽  
Noriko Katayama ◽  
Ryuko Higuchi ◽  
...  

Blood ◽  
1997 ◽  
Vol 89 (12) ◽  
pp. 4646-4651 ◽  
Author(s):  
H.A. Ang ◽  
J.F. Apperley ◽  
K.N. Ward

Abstract Human parvovirus B19 (B19) IgG was studied retrospectively in 66 allogeneic bone marrow transplantation (BMT) patients using an enzyme-linked immunosorbent assay. Recipient and donor sera had been stored pre-BMT together with sequential sera thereafter. Approximately half of donors and recipients had anti-B19 IgG pre-BMT and thus the relative contributions of donor and recipient immunity to antibody production after transplantation could be assessed. For each patient, a serum taken 2 to 3 years after BMT was also tested and the results show that persistence of B19 antibody depends on prior recipient (P = .0003) but not on donor immunity (P = .8). The findings were similar in both sibling and (VUD) BMT volunteer unrelated donor patients. Analysis of sequential post-BMT sera from 41 of the patients, for whom appropriately timed samples were available, showed primary B19 infection in 3 seronegative individuals, whereas 5 others who were seropositive before BMT underwent recurrent infection. Sequential results from the remaining 33 patients without recent B19 infection showed no evidence for donor antibody transfer and confirmed that antibody persistence depends on prior recipient immunity. B19 IgG levels decreased variably with time and some patients eventually became seronegative. It is concluded that this long-term persistence of B19 antibody post-BMT is most probably due to the existence of long-lived recipient plasma cells.


Blood ◽  
2018 ◽  
Vol 132 (22) ◽  
pp. 2351-2361 ◽  
Author(s):  
Lauren P. McLaughlin ◽  
Rayne Rouce ◽  
Stephen Gottschalk ◽  
Vicky Torrano ◽  
George Carrum ◽  
...  

Abstract There is a Blood Commentary on this article in this issue.


2014 ◽  
Vol 98 ◽  
pp. 896
Author(s):  
B. Gao ◽  
C. Rong ◽  
C. Moore ◽  
F. Porcheray ◽  
W. Wong ◽  
...  

Blood ◽  
1988 ◽  
Vol 71 (5) ◽  
pp. 1234-1243 ◽  
Author(s):  
RS Shapiro ◽  
K McClain ◽  
G Frizzera ◽  
KJ Gajl-Peczalska ◽  
JH Kersey ◽  
...  

Abstract B cell lymphoproliferative disorders (BLPD) developed in eight patients following bone marrow transplantation (BMT) for leukemia (five patients) or immunodeficiency (three patients). Recipients of T depleted marrow from a mismatched donor were at particularly high risk of this complication. Six of 25 (24%) recipients of mismatched T depleted bone marrow developed BLPD. In contrast, none of 47 matched T depleted transplants, one of ten (10%) who received non-depleted marrow from an unrelated donor, and only one of 424 matched non-depleted transplants were associated with BLPD. Epstein-Barr virus (EBV) specific serology and DNA hybridization studies demonstrating five to 50 copies of EBV genome/cell in involved tissues implicate this virus as an associated etiologic agent. Restriction fragment length polymorphism (RFLP) and cytogenetic analysis of involved tissue demonstrated donor origin (five of seven) or host origin (two of seven). Histologic appearance was similar to EBV-induced polymorphic B cell proliferations described following solid organ transplantation, or which occur de novo in primary immunodeficiency. Six of seven patients with adequate tissue available for study were found to have monoclonal proliferations by: in situ immunofluorescence (six of seven), and/or immunoglobulin gene rearrangement, (four of six). Cytogenetic analysis of involved tissues from four patients showed a normal karyotype, whereas two had multiple clonal chromosomal abnormalities. Seven patients died despite aggressive attempts at therapy with combinations of antiviral, immunologic, and chemotherapeutic agents.


2020 ◽  
Vol 117 (33) ◽  
pp. 20100-20108
Author(s):  
Yafeng He ◽  
Jianke Ren ◽  
Xiaoping Xu ◽  
Kai Ni ◽  
Andrew Schwader ◽  
...  

Mutation of HELLS (Helicase, Lymphoid-Specific)/Lsh in human DNA causes a severe immunodeficiency syndrome, but the nature of the defect remains unknown. We assessed here the role of Lsh in hematopoiesis using conditional Lsh knockout mice with expression of Mx1 or Vav Cre-recombinase. Bone marrow transplantation studies revealed that Lsh depletion in hematopoietic stem cells severely reduced B cell numbers and impaired B cell development in a hematopoietic cell-autonomous manner. Lsh-deficient mice without bone marrow transplantation exhibited lower Ig levels in vivo compared to controls despite normal peripheral B cell numbers. Purified B lymphocytes proliferated normally but produced less immunoglobulins in response to in vitro stimulation, indicating a reduced capacity to undergo class switch recombination (CSR). Analysis of germline transcripts, examination of double-stranded breaks using biotin-labeling DNA break assay, and End-seq analysis indicated that the initiation of the recombination process was unscathed. In contrast, digestion–circularization PCR analysis and high-throughput sequencing analyses of CSR junctions and a chromosomal break repair assay indicated an impaired ability of the canonical end-joining pathway in Lsh-deficient B cells. Our data suggest a hematopoietic cell-intrinsic role of Lsh in B cell development and in CSR providing a potential target for immunodeficiency therapy.


Sign in / Sign up

Export Citation Format

Share Document